How could AbbVie's new immunology drug affect Johnson & Johnson?
AbbVie's new drug may intensify competition with Johnson & Johnson The development of ABBV-466, a next-generation immunology drug, could increase AbbVie's competitive standing against Johnson & Johnson. ABBV-466, which combines risankizumab with trosunilimab, showed higher rates of remission in patients with Crohn's disease during Phase 2a studies compared to Skyrizi and trosunilimab monotherapy. Since AbbVie and Johnson & Johnson are direct competitors in the biopharmaceutical sector, vying for market share in immunology, the successful progression of ABBV-466 could put pressure on Johnson & Johnson's market position in this therapeutic area.
- Effect
- Mild negative
- How direct
- Brind's reasoning
- When
- Within months
- The story
- No new developments lately
How it reaches Johnson & Johnson
-
AbbVie is developing a next-generation immunology drug, ABBV-466, as a potential successor to Skyrizi. Skyrizi, which generated almost $10 billion in sales in the first half of the year, faces potential biosimilar competition as its patents may expire in the U.S. by 2033. AbbVie recently announced encouraging Phase 2a results for this successor drug.
The full event1independent outlet -
In Phase 2a studies, ABBV-466 achieved higher rates of remission among patients with Crohn's disease than Skyrizi and trosunilimab monotherapy. AbbVie and Johnson & Johnson are direct competitors in the biopharmaceutical sector, vying for market share in oncology and immunology. As a direct competitor in the biopharmaceutical sector, increased strength in the immunology space for AbbVie could translate into competitive pressure on Johnson & Johnson's market share.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
Everything about Johnson & Johnson
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- Skyrizi generated almost $10 billion in sales in the first half of the year, up 27% year over year.fool.com
- ABBV-466 achieved higher rates of remission among patients with Crohn's disease than Skyrizi and trosunilimab monotherapy in Phase 2a.fool.com
- AbbVie and Johnson & Johnson are direct competitors in the biopharmaceutical sector, vying for market share in oncology and immunology.fool.com
- Skyrizi's web of patents may begin to expire in the U.S. by 2033.fool.com
Why it matters
The immunology sector is a massive and critical area of pharmaceutical development, with drugs like Skyrizi being major growth drivers for companies like AbbVie. The ability of AbbVie to successfully transition its market leadership from Skyrizi to a next-generation drug like ABBV-466 is vital for maintaining its financial trajectory and challenging established giants in the field.
Johnson & Johnson operates in a highly competitive biopharmaceutical landscape, where market share in key therapeutic areas like immunology is constantly being contested. The success of a strong competitor's pipeline candidate could force Johnson & Johnson to adjust its strategies, accelerate its own research, or face erosion of its revenue streams in the short to medium term.
What we don't know yet
- Will ABBV-466 successfully confirm its advantages in Phase 3 studies?
- How will Johnson & Johnson respond to increased competition in the immunology market?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- fool.comThursday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.